Pharmaceuticals, Biotechnology and Life Sciences
Allergan has announced today that its first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D) – Viberzi – is now available by prescription in the U.S.
British drugmaker AstraZeneca Plc is in advanced talks to buy privately held cancer drug developer Acerta Pharma BV for more than $5 billion (£3.3 billion).
Johnson & Johnson Monday announced the formation of Verb Surgical Inc., an independent surgical solutions company, in collaboration with Verily Life Sciences…
Horizon Pharma plc has entered a definitive agreement to acquire Crealta Holdings LLC for $510 million in cash.
Alvogen to market Natco’s generic Tamiflu capsules until 2017.
Rhizen Pharmaceuticals has entered into an exclusive, worldwide agreement with Novartis for the development and commercialization of Rhizen’s inhaled dual PI3K-delta gamma inhibitor and its closely related compound for various indications.
The non-interventional XALIA study in patients with deep vein thrombosis (DVT) and a study in patients with cancer-associated thrombosis (CAT) – both showing low rates of major bleeding and recurrent venous thromboembolism (VTE) with Xarelto (rivaroxaban). Results from the two studies were presented at the 2015 ASH Annual Meeting, and XALIA findings were also simultaneously published in the Lancet Haematology.
The U.S. Food and Drug Administration has approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.
The U.S. Food and Drug Administration on Tuesday approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of…
Bristol-Myers Squibb Company has completed the previously announced planned acquisition of Cardioxyl Pharmaceuticals, Inc.